This leading Complement-based Drug Development conference provides a platform to share cutting edge data, understand the current clinical landscape and gain feedback from the industry on the right pathways and indications to target to ensure clinical success.
As the number of companies pursuing complement-based therapeutics is growing with rapidly expanding pipelines, the field is set to explode! The time has come to seize the therapeutic opportunity of complement inhibition, not only in rare disorders but also for more common disease indications. This meeting highlights the clinical developments of druggable complement targets from C5 and beyond.
Don’t miss out on your chance to network with the industry leaders, explore methods to improve clinical trial design to manage potential safety risks and identify translatable biomarkers to ensure successful drug approval.